Four More Reasons Why Investors Should Nix The Pfizer-Allergan Merger

In January 1999, as big pharma was rocked by several mergers, Pfizer’s CEO William Steere dismissed them, claiming that “mergers in this industry are done out of weakness… We’re not weak”. Later that year, he ate these words, arguing instead that Pfizer should buy Warner-Lambert because this merger was done […]

Source: Forbes – Forbes – Management.

Advertisements

Published by

Shawn Boday

Shawn Boday is the CEO of Accretive Technology Group in Seattle, WA.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s